Key Points
- Insider sale: Director Conor Kilroy sold 11,738 shares on April 16 at an average of $7.02 for $82,400.76 to cover tax withholding, trimming his stake by 5.11% to 217,835 shares (≈$1.53M).
- This follows a prior sale on Feb. 17 when Kilroy sold 12,079 shares at $5.05 for about $60,999, indicating multiple recent insider dispositions.
- Context: Aura is a clinical‑stage biopharma (market cap ≈$452.9M) trading near $7 with a 12‑month range of $4.34–$7.48; recent EPS was ($0.37) beating estimates and analysts’ consensus rating is roughly a Hold (average price target $20.50).
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 11,738 shares of Aura Biosciences stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $7.02, for a total transaction of $82,400.76. Following the transaction, the insider owned 217,835 shares in the company, valued at approximately $1,529,201.70. This trade represents a 5.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Conor Kilroy also recently made the following trade(s):
- On Tuesday, February 17th, Conor Kilroy sold 12,079 shares of Aura Biosciences stock. The stock was sold at an average price of $5.05, for a total transaction of $60,998.95.
Aura Biosciences Stock Down 0.4%
NASDAQ AURA opened at $7.06 on Friday. The company has a market capitalization of $452.90 million, a price-to-earnings ratio of -3.94 and a beta of 0.35. Aura Biosciences, Inc. has a twelve month low of $4.34 and a twelve month high of $7.48. The stock has a fifty day simple moving average of $6.16 and a 200 day simple moving average of $5.92.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. Research analysts expect that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Permanent Capital Management LP bought a new position in shares of Aura Biosciences during the 3rd quarter worth about $913,000. Levin Capital Strategies L.P. increased its position in Aura Biosciences by 8.8% in the 3rd quarter. Levin Capital Strategies L.P. now owns 1,627,274 shares of the company's stock valued at $10,057,000 after buying an additional 131,714 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Aura Biosciences during the 1st quarter worth approximately $137,000. MetLife Investment Management LLC raised its stake in Aura Biosciences by 29.3% during the 4th quarter. MetLife Investment Management LLC now owns 25,031 shares of the company's stock worth $136,000 after buying an additional 5,674 shares during the period. Finally, Opal Capital LLC bought a new position in Aura Biosciences in the fourth quarter worth approximately $127,000. 96.75% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have weighed in on AURA shares. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Monday, March 30th. Wall Street Zen upgraded shares of Aura Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aura Biosciences in a research note on Friday, March 27th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $20.50.
Read Our Latest Stock Analysis on AURA
About Aura Biosciences
(
Get Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
